Bio Plus Co

Bio Plus Co Capital Intensity

The Capital Intensity Ratio of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 313.59 %. In the previous year, Capital Intensity Ratio was 397.98 % — a change of -21.21% (lower).

Capital Intensity

313.59 %

YoY

-21.21%

Last updated:

Capital Intensity Ratio of Bio Plus Co is 2025 313.59 % . Capital Intensity Ratio of Bio Plus Co was 2024 397.98 % . It decreases by -21.21% lower compared to the previous year.

The Bio Plus Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
120.33 KRW
Jan 1, 2019
123.36 KRW
Jan 1, 2020
155.69 KRW
Jan 1, 2021
236.41 KRW
Jan 1, 2022
258.32 KRW
Jan 1, 2023
265.68 KRW
Jan 1, 2024
397.98 KRW
Jan 1, 2025
313.59 KRW
The Bio Plus Co Capital Intensity history
YEARCapital IntensityYoY
313.59 %-21.21%
397.98 %+49.80%
265.68 %+2.85%
258.32 %+9.27%
236.41 %+51.85%
155.69 %+26.20%
123.36 %+2.52%
120.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Capital Intensity Ratio of Bio Plus Co is 313.59 % in 2025.

Capital Intensity Ratio of Bio Plus Co changed from 397.98 % to 313.59 %, representing a -21.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bio Plus Co

All Key Metrics — Bio Plus Co